local_hospital

Diagnostichno-Konsultativen Tsentar I Stara Zagora EOOD

Address
Bulevard Ruski 62, 6000 Stara Zagora, Bulgaria

Diagnostichno-Konsultativen Tsentar I Stara Zagora EOOD - Cardiovascular and Renal Disease Research

Diagnostichno-Konsultativen Tsentar I Stara Zagora EOOD is a specialized diagnostic and consultative center engaged in advanced cardiovascular research with a particular focus on complex patient populations. The center contributes to pivotal Phase III clinical investigations examining novel therapeutic approaches for patients with multiple comorbidities affecting both cardiac and renal systems.

  • Heart failure management and novel combination therapies
  • Cardiovascular-renal comorbidity research
  • Advanced therapeutic strategies for chronic heart failure with kidney impairment

The center's research portfolio emphasizes the evaluation of innovative pharmacological interventions, particularly investigating balcinrenone/dapagliflozin combination therapy versus monotherapy in reducing cardiovascular death and heart failure events. Their expertise extends to managing patients with chronic heart failure and comorbid impaired kidney function, focusing on those who have experienced recent heart failure events and require sophisticated therapeutic optimization.

Site Overview

assignment
4
connected trials
corporate_fare
2
sponsors
science
4
IMPs

Activity Indicator

Last 6 months

1
Trials started
0% vs previous period.
1
Trials started 6–12 months ago
4
Total trials linked
Moderately Active
trending_flatStable0%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
4
Sponsors (total)
2
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 476 other sites in Bulgaria

description
Trial volume
4
Outperforms 54% of sites
public
Therapeutic diversity
2areas
Outperforms 47% of sites
groups
Sponsor diversity
2sponsors
Outperforms 38% of sites

Therapeutic Area Benchmark — Bulgaria

Select a therapeutic area to compare against other sites in Bulgaria.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Bulgaria

Market Share

Country: Bulgaria

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Diagnostichno-Konsultativen Tsentar I Stara Zagora EOOD

lock Showing 1 of 4 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Evaluation of Balcinrenone and Dapagliflozin on Cardiovascular Outcomes in Heart Failure Patients with Renal Impairment: A Phase III Randomized, Double-Blind StudyAstraZeneca ABPhase IIIRecruitingJul 2024

IMP list

lock Showing 1 of 4 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Azd50041Unknown

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.